Evidence map›Paper›PMID 37895809›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

The p38-MITOGEN-ACTIVATED PROTEIN KINASE Signaling Pathway Is Involved in

Jian-Hui Lin, Chein-Hui Hung, Yun-Ching Huang, Chih-Shou Chen, Dong-Ru Ho

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jian-Hui LinDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan.
Chein-Hui HungGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.ORCID 0000-0002-3887-6679
Yun-Ching HuangDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan.
Chih-Shou ChenDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan.
Dong-Ru HoDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan.ORCID 0000-0002-1805-0538
Chang Gung University · TWChiayi Chang Gung Memorial Hospital · TW

Funding

Chang Gung Medical Research Project CMRPG6M0161
6 · The paper itself

Abstract

Bladder cancer is a urothelial malignancy. Bladder cancer starts in the urothelial cells lining the inside of the bladder. The 5-year recurrence rate for bladder cancer ranges from 31% to 78%, and the progression rate is approximately 45%. To treat bladder cancer, intravesical drug therapy is often used.

Indexed as

BFTC-905 cellsbladder cancerChinese motherwortG1/G0 arrestLeonurus artemisia extractmitochondrial pathway-dependent apoptosisp38-mitogen-activated protein kinase signaling pathwayreactive oxygen speciesScientific Chinese Medicine extract

Identifiers

PMID37895809
PMCPMC10609973
OpenAlexW4386961161

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.